DE69637749D1 - Getrocknete Blutfaktorzusammensetzung mit Trehalose - Google Patents

Getrocknete Blutfaktorzusammensetzung mit Trehalose

Info

Publication number
DE69637749D1
DE69637749D1 DE69637749T DE69637749T DE69637749D1 DE 69637749 D1 DE69637749 D1 DE 69637749D1 DE 69637749 T DE69637749 T DE 69637749T DE 69637749 T DE69637749 T DE 69637749T DE 69637749 D1 DE69637749 D1 DE 69637749D1
Authority
DE
Germany
Prior art keywords
trehalose
blood factor
factor composition
dried blood
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69637749T
Other languages
English (en)
Inventor
Bruce Joseph Roser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrant Drug Delivery Ltd
Original Assignee
Quadrant Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadrant Drug Delivery Ltd filed Critical Quadrant Drug Delivery Ltd
Application granted granted Critical
Publication of DE69637749D1 publication Critical patent/DE69637749D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69637749T 1995-01-19 1996-01-19 Getrocknete Blutfaktorzusammensetzung mit Trehalose Expired - Lifetime DE69637749D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501040.1A GB9501040D0 (en) 1995-01-19 1995-01-19 Dried composition

Publications (1)

Publication Number Publication Date
DE69637749D1 true DE69637749D1 (de) 2008-12-24

Family

ID=10768253

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69629209T Expired - Lifetime DE69629209T2 (de) 1995-01-19 1996-01-19 Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose
DE69637749T Expired - Lifetime DE69637749D1 (de) 1995-01-19 1996-01-19 Getrocknete Blutfaktorzusammensetzung mit Trehalose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69629209T Expired - Lifetime DE69629209T2 (de) 1995-01-19 1996-01-19 Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose

Country Status (15)

Country Link
US (2) US6649386B2 (de)
EP (4) EP1308170B1 (de)
JP (1) JP3898221B2 (de)
KR (1) KR100417593B1 (de)
CN (1) CN1152713C (de)
AT (2) ATE245442T1 (de)
AU (1) AU704317B2 (de)
CA (2) CA2210872C (de)
DE (2) DE69629209T2 (de)
DK (2) DK1308170T3 (de)
ES (2) ES2316658T3 (de)
GB (1) GB9501040D0 (de)
PT (2) PT1308170E (de)
SI (1) SI1308170T1 (de)
WO (1) WO1996022107A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US6964771B1 (en) 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
US6632648B1 (en) * 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
GB9616536D0 (en) 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
AUPO871997A0 (en) * 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
CN100553678C (zh) 1999-02-22 2009-10-28 巴克斯特国际有限公司 新的无白蛋白的因子ⅷ制剂
CN100436466C (zh) * 2001-08-10 2008-11-26 株式会社林原生物化学研究所 海藻糖或麦芽糖醇和金属离子化合物的缔合物
CA2538794C (en) 2003-09-12 2016-04-19 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US7425539B2 (en) 2004-03-19 2008-09-16 Baxter International Inc. Factor IXa for the treatment of bleeding disorders
DE602005016402D1 (de) * 2004-05-24 2009-10-15 Genvault Corp Stabile lagerung von protein und stabile lagerung von nukleinsäure in wiedergewinnbarer form
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
US8133484B2 (en) 2006-12-15 2012-03-13 Lifebond Ltd Hemostatic materials and dressing
JP2010513462A (ja) * 2006-12-20 2010-04-30 バイエル・ヘルスケア・エルエルシー 第ＶＩＩおよび第ＶＩＩａ因子組成物
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
WO2009082648A1 (en) * 2007-12-21 2009-07-02 Inspiration Biopharmaceuticals, Inc. Stabilized factor ix formulations containing trehalose
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
NZ586383A (en) 2007-12-28 2012-11-30 Baxter Int Recombinant vwf formulations
WO2010031007A2 (en) 2008-09-12 2010-03-18 Genvault Corporation Matrices and media for storage and stabilization of biomolecules
BRPI0919693A2 (pt) 2008-10-21 2020-08-11 Baxter Healthcare S.A formulação farmacêutica estável liofilizada
JP5779780B2 (ja) 2008-11-07 2015-09-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 第ｖｉｉｉ因子製剤
CA2782863A1 (en) 2009-12-22 2011-06-30 Lifebond Ltd Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
CN103782151A (zh) * 2011-07-13 2014-05-07 德纳托股份公司 流体生物样品的稳定化方法
CN102416171B (zh) * 2011-12-06 2013-12-25 中国医学科学院输血研究所 高纯度凝血酶原复合物制品干热病毒灭活过程中的保护剂
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CA2934434C (en) * 2013-12-19 2022-05-24 Crucell Holland B.V. Improved formulations for virosomes.
SG11201700550YA (en) 2014-08-04 2017-02-27 Csl Ltd Factor viii formulation
JP6925980B2 (ja) 2015-05-13 2021-08-25 アジェナス インコーポレイテッド がんの処置および予防のためのワクチン
CN107333750A (zh) * 2017-06-11 2017-11-10 成都吱吖科技有限公司 一种长时血液细胞稳定剂
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
EP4240757A2 (de) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Reinigung von fviii aus plasma mittels siliciumoxidadsorption
WO2022261716A1 (en) * 2021-06-16 2022-12-22 Exopharm Limited Aqueous formulations for preservation of extracellular vesicles

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
WO1987000196A1 (en) * 1985-07-09 1987-01-15 Quadrant Bioresources Limited Protection of proteins and the like
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
EP0182448A3 (de) 1984-08-24 1987-10-28 Genetics Institute, Inc. Verfahren zur Herstellung von Faktor VIII und verwandte Produkte
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
CA2051092C (en) * 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
WO1994007510A1 (en) 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
WO1995003332A1 (en) 1993-07-23 1995-02-02 Baxter International Inc. Activated human factor viii and method of preparation
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
CN100553678C (zh) 1999-02-22 2009-10-28 巴克斯特国际有限公司 新的无白蛋白的因子ⅷ制剂

Also Published As

Publication number Publication date
GB9501040D0 (en) 1995-03-08
AU704317B2 (en) 1999-04-22
ES2202425T3 (es) 2004-04-01
CA2210872A1 (en) 1996-07-25
CA2671383C (en) 2012-04-24
DE69629209D1 (de) 2003-08-28
EP0871476B1 (de) 2003-07-23
DE69629209T2 (de) 2004-02-19
US20020128207A1 (en) 2002-09-12
SI1308170T1 (sl) 2009-04-30
EP2258402A2 (de) 2010-12-08
JPH11503719A (ja) 1999-03-30
EP1974741A1 (de) 2008-10-01
EP1308170B1 (de) 2008-11-12
KR100417593B1 (ko) 2004-04-30
DK0871476T3 (da) 2003-11-10
US7803911B2 (en) 2010-09-28
EP2258402A3 (de) 2011-01-05
EP1308170A3 (de) 2004-03-03
EP0871476A1 (de) 1998-10-21
PT871476E (pt) 2003-12-31
US20090149388A1 (en) 2009-06-11
KR19980701500A (ko) 1998-05-15
EP1308170A2 (de) 2003-05-07
CA2671383A1 (en) 1996-07-25
AU4454096A (en) 1996-08-07
JP3898221B2 (ja) 2007-03-28
ES2316658T3 (es) 2009-04-16
WO1996022107A1 (en) 1996-07-25
CN1152713C (zh) 2004-06-09
CA2210872C (en) 2009-09-08
US6649386B2 (en) 2003-11-18
DK1308170T3 (da) 2008-12-15
ATE413885T1 (de) 2008-11-15
PT1308170E (pt) 2008-12-26
ATE245442T1 (de) 2003-08-15
CN1179107A (zh) 1998-04-15

Similar Documents

Publication Publication Date Title
ATE413885T1 (de) Getrocknete blutfaktorzusammensetzung mit trehalose
IT1276723B1 (it) Formulazioni di analoghi dell'insulina
ES2136105T3 (es) Preparacion farmaceutica y/o cosmetica.
DE3689191T2 (de) Gereinigtes protein mit angiogenischer wirkung und dessen herstellung.
NO893524L (no) Piperazindioner med psykotrop virkning.
DE69107566T2 (de) Flurförderfahrzeug mit Fahrerstandplatz und erhöhter Stabilität.
DK0453603T3 (da) Piroxicamholdige farmaceutiske præparater til topisk anvendelse
DE3675996D1 (de) Mittel mit kontinuierlicher peptidfreisetzung.
FI910112A (fi) Preparat foer lokalt bruk.
NO894592L (no) Pyrrolidon-2-karboksylsyre-derivater med psykotropisk virkning.
DE69309901D1 (de) Aminosäurederivate mit anticholecystokininwirkung
DK330689D0 (da) 1,4-diazepin-derivater med anti-ulcus-virkning
DE3889336T2 (de) Alkyltetramethylcyclohexan-derivate und deren verwendung als duftstoffe.
KR940021732U (ko) 아동용 신발
IT8023998A0 (it) Composizione farmaceutica adattivita' antiflogistica, antipiretica e antalgica.
ITMI932019A0 (it) Composizione farmaceutica antivirale contenente la 2-ammino 4,6-dicloropirimidina e metisoprinolo
DE68909455T2 (de) Polyäthylen-Zusammensetzung.
KR920005118U (ko) 어린이 글자 교습 놀이구
SE9203012D0 (sv) Kaeppen "sven". promenadkaepp med laettmanoevrerad isdubb
DE68916472T2 (de) Polyäthylen-Zusammensetzung.
ITAN940061A0 (it) Calzatura di peso limitato e di elevate capacita' traspiranti
ES1021366Y (es) Calzado infantil
NO884783D0 (no) Anordning for regulering av lys i innendoers oppdrettsanlegg.
ITMI921253A1 (it) Composizione farmaceutica avente attivita' antivirale
IT8117916A0 (it) Calzatura a circolazione d'aria modulata dal piede in marcia od in sosta

Legal Events

Date Code Title Description
8364 No opposition during term of opposition